-
Mashup Score: 17Short-term DAPT, PCI & High Bleeding Risk; Dapagliflozin, Non-Pharmacologic Treatment of HF - American College of Cardiology - 2 day(s) ago
In this week’s View, Dr. Eagle looks at a sex-based analysis of short-term dual antiplatelet therapy (DAPT) in patients receiving percutaneous coronary intervention (PCI) who are deemed at high-risk for bleeding. He then discusses the potential value of dapagliflozin in patients with severe heart failure (HF). Finally, Dr. Eagle explores non-pharmacologic therapies to reduce morbidity and improve function in HF patients. Keywords: Platelet Aggregation Inhibitors, Percutaneous Coronary Intervention,
Source: www.acc.orgCategories: General Medicine News, CardiologistsTweet
In this week’s #EaglesEyeView, Dr. @keaglemd looks at a sex-based analysis of short-term #DAPT in patients receiving #PCI who are deemed at high-risk for bleeding. He also discusses dapagliflozin & non-pharmacologic treatment of HF. 🎧 Tune in here: https://t.co/9ZLlVAfad5 https://t.co/Z0SJqiLc27